Nefazol

Quick links to important sections

Nefazol

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nefazol

Property Description
Active ingredient Cefazolin (Cefazolin sodium)
Form Powder for injection
Pharmacological class Beta-Lactam antibiotic; First-generation cephalosporin
General purpose To combat bacterial infections and provide surgical prophylaxis
Origin Semi-synthetic

Nefazol: The Definition and Pharmacological Class

Nefazol is a prescription-only medicine (Rx) containing the active ingredient Cefazolin, which is a semi-synthetic beta-Lactam antibiotic. This drug belongs to the first-generation cephalosporin group of antibacterial agents, a classification that is clinically recognized for its targeted effectiveness against many Gram-positive bacteria. Cefazolin is a single-ingredient product, and the International Nonproprietary Name (INN) is classified as an essential medicine, confirming its fundamental importance for public health.

Form and Type: The Definitive Injection

Cefazolin is supplied as a sterile powder for injection, a form that ensures its stability prior to mixing. This preparation requires reconstitution with a sterile vehicle, such as Sterile Water for Injection or Sodium Chloride solution, before administration. The necessity of this dosage form is due to the poor absorption of Cefazolin via the digestive system. The resulting solution is administered via the parenteral route (Intravenous or Intramuscular injection), a method necessary to ensure reliable systemic availability.

General Purpose and Function

The general purpose of Cefazolin is to function as a bactericidal agent to definitively combat bacterial infections caused by susceptible microorganisms. Its primary function is achieved by interfering with the unique structural component of bacteria: the cell wall. This mode of action ensures the rapid elimination of the microbes. A typical use scenario involves its application for surgical prophylaxis—preventing infection before certain medical procedures—where it targets the bacteria most commonly associated with such complications.

What side effects are possible with Nefazol?

The possible side effects and safety profile of Nefazol (Cefazolin) are formally documented by regulatory authorities, classifying documented adverse reactions primarily by frequency and the body system affected.

Adverse Reaction Scope

Category Description / Official Listing
Common Reactions Effects that appear frequently, including diarrhea, nausea, and vomiting. Local reactions such as pain or induration at the injection site may also occur.
System-Organ Classes Involved Adverse reactions are documented across several systems, including Gastrointestinal Disorders, Immune System Disorders (e.g., rash, itching), Blood and Lymphatic System Disorders (e.g., transient changes in blood cell counts), and Renal Disorders (e.g., elevations in BUN/Creatinine).
Serious Adverse Reactions (SARs) Official labeling highlights rare but severe reactions, including anaphylaxis (a serious hypersensitivity reaction), Clostridioides difficile-associated diarrhea (CDAD), and the potential for seizures or CNS toxicity in certain populations.

Safety Considerations

Official regulatory documents define specific limitations and population-based risks:

  • Contraindication: Nefazol is officially contraindicated in patients with a history of immediate hypersensitivity reactions (such as anaphylaxis) to Cefazolin or any other drug in the cephalosporin or beta-lactam class of antibiotics.
  • Renal Impairment: Patients with reduced renal function are at an increased risk of CNS toxicity and seizures due to reduced drug clearance. Official prescribing information mandates dosage adjustment in this population.
  • Exposure-Related Risk: Prolonged use of the medication may be associated with the potential for superinfection, which is the overgrowth of bacteria or fungi not susceptible to the medicine.

Connection to the Overall Safety Profile

The official safety profile structures the understanding of risks by standardizing adverse event terminology and frequency, explicitly defining the most serious outcomes (SARs), and specifying constraints like contraindications and required dosage modifications for individuals with renal impairment. This structured classification formalizes the comprehensive safety characteristics of the drug.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Nefazol (nefazodone) should be treated as a serious medical situation requiring prompt attention. While documented outcomes of nefazodone overdose alone have generally been non-fatal, fatalities have been reported, predominantly in cases where the drug was taken in combination with alcohol or other substances.

Symptoms of Overdose

The most commonly reported symptoms following an overdose of nefazodone include nausea, vomiting, and extreme drowsiness (somnolence). More serious, though less frequent, manifestations reported in overdose situations include convulsion (seizure). These physiological effects primarily involve the gastrointestinal and central nervous systems.

Required Emergency Actions

Immediate medical help is required if the person who has taken an overdose exhibits critical symptoms. You must call emergency services (such as 911) if the individual has:

  • Collapsed or lost consciousness.
  • Experienced a seizure or convulsion.
  • Developed trouble breathing or stopped breathing.
  • Cannot be awakened.

For other cases, or if you require additional guidance on the treatment of an overdose, contact a poison control center immediately. The management of any overdose typically involves general supportive and symptomatic measures, including ensuring adequate airway, oxygenation, and monitoring vital signs. Always inform medical staff of the dose taken and any other substances involved.

Therapeutic Uses of Nefazol

What Nefazol Treats: Main Uses and Benefits

Nefazol is commonly used across conditions presenting with acute or disruptive episodes caused by susceptible bacteria. It is an established option for managing infections that produce a heightened symptomatic burden.

Nefazol is applied in clinical settings that involve heightened systemic burden, primarily for the treatment of severe established infections such as those affecting the blood (septicemia), bones and joints (osteomyelitis), heart valves, and deep tissues (e.g., pneumonia or severe skin infections). It is also relevant in the perioperative context to provide crucial short-term symptomatic support by reducing the risk of surgical site infections (SSI).

Therapy, when appropriate, may assist in managing symptoms that interfere with daily functioning, such as persistent high fever and severe malaise, which contributes to easing the overall symptom load during the acute illness phase. The medication is also relevant for managing localized inflammation, including the swelling, heat, redness, and pain associated with cellulitis.

Quick Fact: Relief for Systemic Discomfort

Quick Fact: Relief for Systemic Discomfort. This medication is commonly used to help manage the high fever and overall feeling of illness (malaise) that accompany severe bacterial infections, thereby contributing to improved comfort during symptomatic periods.

Regulatory References

  1. NIH DailyMed official Cefazolin label

Eligibility and Restrictions for Use

Who can and cannot use Nefazol?

This section outlines the official population eligibility and non-eligibility rules for Nefazol, as stated in government regulatory documents.

Contraindicated Populations

The use of Nefazol is strictly contraindicated for any individual with a documented history of hypersensitivity or allergic reaction to Cefazolin, the cephalosporin class of antibiotics, or other beta-lactam drugs like penicillin. This absolute prohibition is based on the risk of immediate, serious cross-hypersensitivity reactions.

Age and Developmental Eligibility

Nefazol is generally approved for use in adults and in pediatric patients one month of age and older for the treatment of approved infections. Use is formally not recommended in infants under one month, including neonates, as the safety and efficacy have not been established by regulatory bodies. Furthermore, use for surgical prophylaxis may be restricted in children younger than ten years.

Conditional and Restricted Use

Eligibility is conditional upon specific physiological factors. Patients with impaired renal function (kidney function) fall into a restricted population and require mandatory dosage adjustment as documented in the prescribing information. Caution is also advised when prescribing the medicine to nursing mothers, as low concentrations of Cefazolin are known to be present in breast milk. Certain other conditions, including a history of colitis or a known seizure disorder, require special consideration upon administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Cefazolin, the active ingredient in Nefazol, details specific interaction patterns concerning other medicines and certain laboratory procedures. These documented interactions focus on drug clearance mechanisms, effects on coagulation, and analytical interference.

Pharmacokinetic Interactions and Restrictions

Co-administration with Probenecid is officially not recommended due to its role in affecting the drug’s elimination process. Probenecid inhibits the renal tubular secretion of Cefazolin. This pharmacokinetic mechanism results in increased and more prolonged Cefazolin concentrations in the blood, which regulatory documents describe as altered systemic exposure.

Pharmacodynamic Effects and Monitoring

A significant pharmacodynamic interaction involves agents affecting blood clotting. Cefazolin is associated with a potential fall in prothrombin activity, which can heighten the risk of bleeding for individuals receiving concurrent anticoagulant therapy. The official labeling indicates that this interaction is a particularly important consideration for patients with pre-existing conditions such as renal impairment, hepatic impairment, or those in a poor nutritional state.

Interference with Laboratory Tests

The regulatory information also documents a procedural constraint regarding diagnostic testing. Cefazolin may cause a false positive reaction for glucose when the urine is tested using certain non-enzyme-based, copper-reduction methods, such as CLINITEST tablets. Enzyme-based urinary glucose tests are not noted to exhibit this interference.

Mechanism of Action

Inactivation of Essential Bacterial Enzymes

Nefazol's core mechanism involves the covalent inactivation of Penicillin-Binding Proteins (PBPs), the bacterial transpeptidase enzymes responsible for constructing the protective cell wall. By irreversibly blocking the cross-linking step of peptidoglycan synthesis, the drug prevents the microbe from building its rigid structure.


Mechanism Leading to Cell Lysis

This molecular blockade triggers a mechanistic cascade that leads to the bactericidal effect. The resultant weakness in the cell wall means the bacterium cannot withstand its own high internal osmotic pressure, causing it to burst in a process called lysis. This process is often accelerated by the activation of the microbe's own destructive enzymes, ultimately leading to the physical elimination of the targeted organisms.


Limitations by Microbial Counter-Mechanism

The effectiveness of this cell-wall mechanism is biologically constrained by the presence of beta-Lactamase enzymes in some bacteria. These microbial counter-mechanisms chemically inactivate Nefazol before it can reach its target, defining the boundaries of the drug's physiological effect profile.

Dosage and Administration Information

Official Administration Instructions (Nefazodone)

These instructions outline the standardized use of the medicine. This information is not clinical advice and excludes all warnings, precautions, and therapeutic indications.


Administration Route and Timing

The medicine is supplied as tablets and must be taken orally (by mouth). It should be taken twice daily (BID), which means in two divided doses per day, and may be taken with or without food.

Dosing and Adjustment Schedule

Official instructions specify a gradual, incremental dosing regimen.

Population Initial Dose Dosing Frequency Dose Adjustment Rule
Adults 200 mg per day (100 mg BID) Twice Daily (BID) Increase by 100–200 mg/day at intervals of no less than one week
Elderly/Debilitated 100 mg per day (50 mg BID) Twice Daily (BID) Adjustments should be in smaller increments and at longer intervals than in younger patients

The usual therapeutic dosing range is between 300 mg and 600 mg per day.

If a Dose is Missed

If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and return to the regular dosing schedule. Do not double doses to make up for the missed one.

Duration of Use

It may take several weeks to achieve the full effect of the medicine. The drug is intended for continued use, and the necessity of continued treatment should be assessed periodically.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nefazol (Cefazolin)


Evidence for Use in Surgical Prophylaxis

Research into Nefazol's use in surgical prophylaxis—used in research exploring the prevention of infections before and immediately after surgery—was evaluated in numerous studies. The evidence is based primarily on Randomized Controlled Trials (RCTs) and systematic reviews, which are used to evaluate and synthesize research findings. Studies examined how Nefazol compared to either no treatment or to other antibiotic agents in groups of adult patients undergoing various procedures, including orthopedic, cardiac, and gynecological surgeries.

Studies monitored patterns related to infection rates measured during the study period, focusing on the incidence of Surgical Site Infections (SSIs). Findings described patterns observed in the studies that align with the specific outcomes measured and tracked in published scientific literature.

However, certain limitations in the research base are noted in scientific reviews. For instance, many supporting RCTs were conducted some time ago and may not fully reflect modern surgical techniques.

Evidence for Use in Established Systemic Infections

Research explored the use of Nefazol for various conditions associated with acute or disruptive episodes, such as established bone and joint infections, severe skin infections, and bloodstream infections (bacteremia). The evidence for treating these complex, established infections often comes from retrospective observational cohort studies and systematic reviews rather than large-scale, dedicated head-to-head RCTs.

Research monitored outcomes related to physiological strain or stress, specifically measuring long-term survival, rates of clinical cure, and whether the infection returned (relapse or recurrence). For infections where the source is a Gram-positive bacterium, research describes its inclusion in the evidence landscape.

Because the evidence often relies on analyzing existing data, the evidence quality varies across studies and the certainty regarding comparative outcomes remains low compared to controlled trials. There is also limited information for long-term outcomes beyond the initial 30-to-90-day period for some deep-seated infections.


What Is Still Uncertain About Nefazol's Research Base

One notable limitation is the comparative evidence is lacking in the form of dedicated, head-to-head RCTs against some of the newer, alternative antibiotics used today for severe infections. Research is ongoing into the clinical importance of the Cefazolin Inoculum Effect (CzIE), which is a specific area of scientific uncertainty regarding the drug's activity. The evidence highlights what is known—and what is still uncertain—about this medicine.

Frequently Asked Questions (FAQ)

Common questions about Nefazol (FAQ)

Q: Is Nefazol considered a controlled substance?

Official drug classifications indicate that Nefazol (cefazolin) is not scheduled as a controlled substance in the United States. It is a prescription-only medication, but it does not carry the same regulatory restrictions as controlled medicines.

Q: How does Nefazol compare to other medications used for similar purposes?

Regulatory classification places Nefazol in the first-generation cephalosporin group of antibiotics. This means its spectrum of activity, or the range of bacteria it targets, is generally narrower compared to later-generation cephalosporins used for different or broader types of infections.

Q: Do the side effects of Nefazol typically go away over time?

Information about side effects indicates that many may subside after the medication is discontinued. However, it is noted in official information that some serious adverse reactions, such as Clostridium difficile-associated diarrhea, can potentially occur up to two or more months after treatment has concluded.

Q: What is the expected duration of the effects of Nefazol?

The effect of a single dose is related to how long the drug stays in the body. For individuals with normal kidney function, the elimination half-life of cefazolin is reported to be approximately 1 to 2 hours. This is the time it takes for the amount of medicine in the bloodstream to be reduced by half.

Q: Are there specific foods or drinks to avoid when taking Nefazol?

Official drug information indicates that individuals should generally continue their normal diet while receiving Nefazol. It is not associated with restrictions on specific foods or beverages unless a healthcare professional advises otherwise due to a separate medical condition.

Q: Does Nefazol interact with common over-the-counter pain relievers?

Drug interaction information lists potential interactions with common pain relievers, including acetaminophen and acetylsalicylic acid (aspirin). These interactions may result in an increase in the concentration of Nefazol in the blood.

Q: Can Nefazol be taken with vitamins or herbal supplements?

Regulatory information advises patients to maintain a comprehensive list of all prescription and nonprescription medicines, as well as dietary supplements and vitamins, for their healthcare provider. This information is reviewed for potential interactions before administration.

Q: Is Nefazol safe for elderly patients to use?

Clinical studies showed no overall difference in safety or effectiveness between elderly and younger adult patients. However, official documents note that a greater sensitivity in some older individuals cannot be ruled out, often due to underlying health conditions.

Q: Is Nefazol safe to use during pregnancy or while breastfeeding?

Regarding pregnancy, official documents advise that the medicine should be used only if clearly needed and the potential benefit outweighs the risk. During breastfeeding, cefazolin is known to be present in low concentrations in breast milk, which is a factor healthcare professionals consider.

Q: If I stop taking Nefazol suddenly, will I have withdrawal symptoms?

Regulatory documents do not use the term 'withdrawal' in relation to stopping Nefazol. However, stopping treatment prematurely or missing doses may result in the infection not achieving full resolution, leading to bacteria potentially becoming resistant to the antibiotic.

Q: Why is Nefazol sometimes prescribed for long-term use?

Nefazol is officially indicated for treating specific, complex conditions such as Bone and Joint Infections caused by susceptible organisms. These types of severe, deep-seated infections often require extended courses of antibacterial therapy.

Q: What happens if Nefazol is taken with alcohol?

Official and clinical warnings mention that alcohol consumption is not recommended while receiving this medication. This is due to the potential risk of experiencing a disulfiram-like reaction, which can cause unpleasant symptoms such as flushing, headaches, and a drop in blood pressure.

Q: Is it normal to feel tired or dizzy when starting Nefazol?

Official safety profiles indicate that dizziness and tiredness (also referred to as weakness or fatigue) are among the reported side effects of this medicine. As with any medication, individual responses can vary.

Q: Does Nefazol affect my ability to drive or operate machinery?

Because reported side effects include dizziness, confusion, and the potential for seizures (a serious adverse reaction), official information suggests the medicine may affect mental alertness. These potential effects may impair the ability to drive or operate machinery.

Q: Are there any long-term health risks associated with taking Nefazol?

Official safety information indicates that prolonged use of the medication is associated with the potential for superinfection. This is the overgrowth of bacteria or fungi that are not susceptible to Nefazol. Prolonged use also carries an increased risk of Clostridium difficile-associated diarrhea (CDAD).

Q: Can Nefazol cause changes in mood or behavior?

Reported adverse reactions involving the central nervous system (CNS) include symptoms such as confusion, restlessness, and anxiety. These effects relate to the overall mental state.

Q: Is Nefazol available as a generic medicine?

Official marketing status shows that Cefazolin is available under an Abbreviated New Drug Application (ANDA). This designation is used for generic drug products that the FDA has approved as being therapeutically equivalent to the original brand-name product.

Q: Do I need to have a special test before starting Nefazol?

While no mandatory baseline testing is required for all patients, official documents note that it may be useful to monitor kidney (renal) function. This is particularly relevant for elderly patients and individuals with known kidney impairment, who require dosage adjustment.

Q: Does Nefazol show up on drug screening tests?

Regulatory information documents a procedural constraint regarding diagnostic testing. Cefazolin may cause a false positive reaction for glucose when the urine is tested using certain copper-reduction methods, such as CLINITEST tablets. It is not generally known to interfere with standard drug screening tests.

Q: Why do some people experience trouble sleeping while on Nefazol?

While not listed as a common effect, the safety profile includes drowsiness (somnolence) as a reported adverse reaction. Changes in wakefulness and alertness, such as drowsiness, can potentially affect a patient’s sleep cycle.

Q: Can Nefazol interact with birth control pills?

There is a documented low risk of interaction with oral contraceptives (birth control pills). Cefazolin may decrease the level or effect of oral estrogen and progestin-containing contraceptives by altering the normal bacterial flora in the intestines.

Q: Does Nefazol affect blood pressure?

Official safety data includes reports of both hypotension (low blood pressure) and increased blood pressure (hypertension) as possible side effects. These effects are documented in official regulatory listings.

Q: Is it true that Nefazol can change my appetite?

Official drug safety listings include loss of appetite (anorexia) as a reported side effect of this medication. This is typically categorized under gastrointestinal disorders.

Q: How is Nefazol eliminated from the body?

Official pharmacokinetic information states that Nefazol is primarily removed from the body by the kidneys. It is excreted unchanged in the urine through two processes: renal tubular secretion and glomerular filtration.

Q: Is Nefazol taken daily or only as needed?

Dosing frequency depends on the condition being treated. For established infections, the medication is administered multiple times per day. For use in surgical prophylaxis (prevention), the treatment course is generally much shorter, often less than 24 hours. The exact frequency is determined by the patient's condition and prescribed by a healthcare provider.

Q: Is Nefazol commonly associated with weight gain or loss?

While the frequency is not known, official regulatory documents list both unusual weight loss and weight gain as reported side effects. These effects are classified as adverse reactions.

Q: Why do official sources list a black box warning for Nefazol?

Official regulatory documents from the FDA do not currently list a Boxed Warning (often called a Black Box Warning) for Cefazolin. This warning is reserved for the most serious safety issues associated with a drug.

Q: Can Nefazol affect my liver function?

Adverse effects on the liver have been reported, including a transient rise in liver enzymes (such as SGOT and SGPT). There have also been occasional reports of hepatitis (liver inflammation).

How should Nefazol be stored and disposed of?

Storage Requirements

Nefazol (Cefazolin sodium powder for injection) must be stored at Controlled Room Temperature (20 C to 25 C). The dry powder should be protected from light and kept away from excessive heat or freezing. The medication must be kept out of the reach of children.

After the powder is mixed with a sterile diluent, the resulting solution has a time-limited stability. The solution must be used within the specified time, typically 4 to 24 hours at room temperature, or up to 10 days if refrigerated (2 C to 8 C), depending on the concentration. Any unused portion of the solution must be discarded after the expiration of the stability period.

Disposal Instructions

Unused or expired Cefazolin should not be flushed down the toilet. Disposal should follow established guidelines, such as utilizing a drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an unappealing substance like dirt or used coffee grounds, sealed in a bag, and then placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nefazol found in:

A-Z Index: